Antibody therapy for treatment of diseases associated with gluten intolerance
The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or gluten-derived peptides. Such diseases include, for example, celiac disease and dermatitis herpetiformis.
1. A pharmaceutical composition comprising an anti-gluten antibody and a pharmaceutically acceptable carrier wherein the antibody is isolated from milk or colostrum of a ruminant such as a cow, goat or sheep that has been immunized with an adjuvant in combination with gluten, gliadin, glutenin, a gluten derived peptide or any combination thereof and wherein the gluten-derived peptide is selected from the following α-gliadin peptides: LGQQQPFPPQQPYPQPQPF (SEQ ID NO: 1); LGQQQPFPPQQPY (SEQ ID NO: 2); QLQPFPQPQLPY (SEQ ID NO: 3); and LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 4).
2. The pharmaceutical composition of claim 1 where the glutamine residues in the gluten, gliadin, glutenin or gluten-derived peptide have been partially or fully deamidated prior to immunization of the ruminant used to generate the anti-gluten antibody.
3. The pharmaceutical composition of claim 1 formulated for oral delivery to a patient.
4. A pharmaceutical composition comprising an isolated anti-gluten antibody and a pharmaceutically acceptable carrier wherein the anti-gluten antibody is specific for a toxic peptide from gluten wherein the toxic peptide derived from gluten is selected from the following α-gliadin peptides:
LGQQQPFPPQQPYPQPQPF;
(SEQ ID NO: 1)
LGQQQPFPPQQPY;
(SEQ ID NO: 2)
QLQPFPQPQLPY;
(SEQ ID NO: 3)
and
LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF.
(SEQ ID NO: 4)
5. The pharmaceutical composition of claim 4 wherein the antibody inhibits activation of the innate immune system.
6. The pharmaceutical composition of claim 4 wherein the antibody inhibits the stimulation of T cell clones or T cell lines specific for the toxic peptide.
7. The pharmaceutical composition of claim 4 , wherein the anti-gluten antibody is present in the composition in a dosage range of 1 mg/kg-500 mg/kg body weight per dose.
8. The pharmaceutical composition of claim 4 wherein the anti-gluten antibody is isolated from milk.
9. A pharmaceutical composition comprising an anti-gluten antibody and a pharmaceutically acceptable carrier wherein the antibody is isolated from milk or colostrum and wherein the anti-gluten antibody is specific for a toxic peptide from gluten wherein the toxic peptide derived from gluten is selected from the following α-gliadin peptides: LGQQQPFPPQQPYPQPQPF (SEQ ID NO: 1); LGQQQPFPPQQPY (SEQ ID NO: 2); QLQPFPQPQLPY (SEQ ID NO: 3); LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 4); and any combination thereof.
10. The pharmaceutical composition of claim 9 , wherein the anti-gluten antibody is present in the composition in a dosage range of 5 mg/kg-50 mg/kg body weight per dose.